Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089059040> ?p ?o ?g. }
Showing items 1 to 69 of
69
with 100 items per page.
- W3089059040 endingPage "100235" @default.
- W3089059040 startingPage "100235" @default.
- W3089059040 abstract "This work was supported by a grant from the National Research Foundation of Korea (NRF) funded by the Korea government (MSIP) (NRF-2018R1A2B6006199) and a research grant from Ahn-Gook Pharmaceutical Co, Ltd, Seoul, Republic of Korea. Platelet activating factor (PAF) is one of the most potent phospholipid released from platelets as well as various inflammatory cells. PAF has been known to play a role in the regulation of immune responses and allergic inflammation. This study was aimed to compare circulating levels of PAF and PAF-acetylhydrolase (AH) which can catabolize PAF in patients with chronic spontaneous urticarial (CSU) and healthy controls (NC) and to investigate relationships of their levels and urticaria severity and therapeutic response. Serum PAF and PAF-AH levels were measured by ELISA in 283 CSU patients and 111 age- and sex-matched NCs. Urticaria severity was evaluated by urticaria activity score over 7 days (UAS7). Within 3 months after measuring PAF levels, patients whose urticaria was not controlled by antihistamine treatment were classified as histamine receptor 1 antagonist (H1RA) non-responders. Serum PAF levels were higher in CSU patients than in NCs (median 4368.9 [17.0–14768.3] vs. 3256.4 [27.1–13886.7] pg/ml, p = 0.015), while serum PAF-AH levels were lower in CSU patients (105.6 [2.6–296.4] vs. 125.7 [2.0–291.1] ng/ml, p = 0.001). H1RA non-responders had higher levels of PAF (3804.5 [17.0–11716.3] vs. 5426.3 [53.1–14768.3], p < 0.001) in their sera. A generalized linear model revealed that a higher UAS7 score (odds ratio 1.023) and a PAF level ≥ 5000 pg/ml (1.409) were significant predictors of a poor response to H1RA treatment. CSU patients, particularly those with H1RA refractoriness, showed significant increases in serum PAF levels and decreases in PAF-AH as compared with NCs. Therapies modulating PAF and PAF-AH levels could be effective in patients with CSU refractory to antihistamines." @default.
- W3089059040 created "2020-10-01" @default.
- W3089059040 creator A5028415031 @default.
- W3089059040 creator A5038852974 @default.
- W3089059040 creator A5040691618 @default.
- W3089059040 creator A5044524626 @default.
- W3089059040 creator A5052722112 @default.
- W3089059040 creator A5091474946 @default.
- W3089059040 date "2020-08-01" @default.
- W3089059040 modified "2023-09-25" @default.
- W3089059040 title "Serum platelet activating factor levels predicts refractoriness to antihistamine treatment in chronic spontaneous urticaria" @default.
- W3089059040 doi "https://doi.org/10.1016/j.waojou.2020.100235" @default.
- W3089059040 hasPublicationYear "2020" @default.
- W3089059040 type Work @default.
- W3089059040 sameAs 3089059040 @default.
- W3089059040 citedByCount "0" @default.
- W3089059040 crossrefType "journal-article" @default.
- W3089059040 hasAuthorship W3089059040A5028415031 @default.
- W3089059040 hasAuthorship W3089059040A5038852974 @default.
- W3089059040 hasAuthorship W3089059040A5040691618 @default.
- W3089059040 hasAuthorship W3089059040A5044524626 @default.
- W3089059040 hasAuthorship W3089059040A5052722112 @default.
- W3089059040 hasAuthorship W3089059040A5091474946 @default.
- W3089059040 hasBestOaLocation W30890590401 @default.
- W3089059040 hasConcept C1122143 @default.
- W3089059040 hasConcept C126322002 @default.
- W3089059040 hasConcept C170493617 @default.
- W3089059040 hasConcept C203014093 @default.
- W3089059040 hasConcept C207480886 @default.
- W3089059040 hasConcept C2776880894 @default.
- W3089059040 hasConcept C2776885963 @default.
- W3089059040 hasConcept C2776914184 @default.
- W3089059040 hasConcept C2779020240 @default.
- W3089059040 hasConcept C71924100 @default.
- W3089059040 hasConcept C89560881 @default.
- W3089059040 hasConcept C90924648 @default.
- W3089059040 hasConceptScore W3089059040C1122143 @default.
- W3089059040 hasConceptScore W3089059040C126322002 @default.
- W3089059040 hasConceptScore W3089059040C170493617 @default.
- W3089059040 hasConceptScore W3089059040C203014093 @default.
- W3089059040 hasConceptScore W3089059040C207480886 @default.
- W3089059040 hasConceptScore W3089059040C2776880894 @default.
- W3089059040 hasConceptScore W3089059040C2776885963 @default.
- W3089059040 hasConceptScore W3089059040C2776914184 @default.
- W3089059040 hasConceptScore W3089059040C2779020240 @default.
- W3089059040 hasConceptScore W3089059040C71924100 @default.
- W3089059040 hasConceptScore W3089059040C89560881 @default.
- W3089059040 hasConceptScore W3089059040C90924648 @default.
- W3089059040 hasIssue "8" @default.
- W3089059040 hasLocation W30890590401 @default.
- W3089059040 hasOpenAccess W3089059040 @default.
- W3089059040 hasPrimaryLocation W30890590401 @default.
- W3089059040 hasRelatedWork W1995987460 @default.
- W3089059040 hasRelatedWork W1999247701 @default.
- W3089059040 hasRelatedWork W2002313556 @default.
- W3089059040 hasRelatedWork W2012152399 @default.
- W3089059040 hasRelatedWork W2076210407 @default.
- W3089059040 hasRelatedWork W2409868487 @default.
- W3089059040 hasRelatedWork W2418153053 @default.
- W3089059040 hasRelatedWork W2893040706 @default.
- W3089059040 hasRelatedWork W3026843203 @default.
- W3089059040 hasRelatedWork W4233199994 @default.
- W3089059040 hasVolume "13" @default.
- W3089059040 isParatext "false" @default.
- W3089059040 isRetracted "false" @default.
- W3089059040 magId "3089059040" @default.
- W3089059040 workType "article" @default.